Kura Oncology’s (KURA) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Monday morning, RTT News reports. The brokerage currently has a $37.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Up 1.8 %

NASDAQ KURA opened at $17.84 on Monday. The business has a fifty day moving average price of $18.90 and a 200 day moving average price of $20.01. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. The company has a market cap of $1.37 billion, a P/E ratio of -8.00 and a beta of 0.86. Kura Oncology has a one year low of $8.17 and a one year high of $24.17.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter last year, the business earned ($0.53) EPS. The firm’s revenue was up .0% on a year-over-year basis. Research analysts anticipate that Kura Oncology will post -2.46 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Several hedge funds have recently modified their holdings of the stock. nVerses Capital LLC purchased a new stake in Kura Oncology during the 3rd quarter worth about $25,000. SG Americas Securities LLC purchased a new position in Kura Oncology in the first quarter valued at approximately $110,000. Quarry LP acquired a new stake in Kura Oncology during the 2nd quarter worth $196,000. Entropy Technologies LP acquired a new stake in shares of Kura Oncology during the first quarter worth about $218,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kura Oncology by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after purchasing an additional 5,788 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.